Trial
NCT03168100
2017-03: A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule F7 (Anti-SLAMF7) Monoclonal Antibody (mAb) Therapy After Autologous Stem Cell Transplant in Patients With Multiple Myeloma
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
University of Arkansas
Collaborators
—
Condition
Multiple Myeloma
Intervention
Elotuzumab
Why stopped
No study population. No subjects enrolled.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-01-28